Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy

Gynecologic Oncology

Volumn 106, Issue 2, 2007, Pages 381-387

  Eisenhauer, Eric L ^a   Tew, William P ^a   Levine, Douglas A ^a   Lichtman, Stuart M ^a   Brown, Carol L ^a   Aghajanian, Carol ^a   Huh, Jae ^a   Barakat, Richard R ^a   Chi, Dennis S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Combination chemotherapy; Elderly patients; Ovarian cancer; Platinum taxane chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; ELDERLY CARE; ELECTROLYTE DISTURBANCE; FEMALE; HEARING LOSS; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 34447628517     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.04.012     Document Type: Article

References (42)

1. Edwards B.K., Howe H.L., Ries L.A., Thun M.J., Rosenberg H.M., Yancik R., et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94 (2002) 2766-2792
2. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 80 (1997) 1273-1283
3. Thigpen T., Brady M.F., Omura G.A., Creasman W.T., McGuire W.P., Hoskins W.J., et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 71 2 Suppl (1993) 606-614
4. Hightower R.D., Nguyen H.N., Averette H.E., Hoskins W., Harrison T., and Steren A. National survey of ovarian carcinoma. IV: patterns of care and related survival for older patients. Cancer 73 (1994) 377-383
5. Sundararajan V., Hershman D., Grann V.R., Jacobson J.S., and Neugut A.I. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 20 (2002) 173-178
6. Omura G., Blessing J.A., Ehrlich C.E., Miller A., Yordan E., Creasman W.T., et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 57 (1986) 1725-1730
7. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 (1996) 1-6
8. Hershman D., Jacobson J.S., McBride R., Mitra N., Sundararajan V., Grann V.R., et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol 94 (2004) 540-549
9. Pignata S., and Vermorken J.B. Ovarian cancer in the elderly. Crit Rev Oncol Hematol 49 (2004) 77-86
10. Alberts D.S., Dahlberg S., Green S.J., Garcia D., Hannigan E.V., O'Toole R., et al. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer 71 2 Suppl (1993) 618-627
11. Edmonson J.H., Su J., and Krook J.E. Treatment of ovarian cancer in elderly women. Mayo Clinic-North Central Cancer Treatment Group studies. Cancer 71 suppl 2 (1993) 615-617
12. Chiara S., Lionetto R., Vincenti M., Bruzzone M., Nobile M.T., Gadducci A., et al. Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy. Crit Rev Oncol Hematol 37 (2001) 27-34
13. Lichtman S.M., Hollis D., Miller A.A., Rosner G.L., Rhoades C.A., Lester E.P., et al. Cancer and Leukemia Group B (CALGB 9762). Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 24 (2006) 1846-1851
14. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
15. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
16. Rustin G.J., Nelstrop A.E., Tuxen M.K., and Lambert H.E. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 7 (1996) 361-364
17. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1996) 163-170
19. Cox D.R. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
20. Markman M., Lewis Jr. J.L., Saigo P., Hakes T., Jones W., et al. Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience. Cancer 71 2 Suppl (1993) 634-637
21. Trimble E.L., Carter C.L., Cain D., Freidlin B., Ungerleider R.S., and Friedman M.A. Representation of older patients in cancer treatment trials. Cancer 74 7 Suppl (1994) 2208-2214
22. Hutchins L.F., Unger J.M., Crowley J.J., Coltman Jr. C.A., and Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341 (1999) 2061-2067
23. Ries L.A. Ovarian cancer. Survival and treatment differences by age. Cancer 71 suppl 2 (1993) 524-529
24. Bruchim I., Altaras M., and Fishman A. Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol Oncol 86 (2002) 274-278
25. Susini T., Scambia G., Margariti P.A., Giannice R., Signorile P., Benedetti Panici P., et al. Gynecologic oncologic surgery in the elderly: a retrospective analysis of 213 patients. Gynecol Oncol 75 (1999) 437-443
26. Nordin A.J., Chinn D.J., Moloney I., Naik R., de Barros Lopes A., and Monaghan J.M. Do elderly cancer patients care about cure? Attitudes to radical gynecologic oncology surgery in the elderly. Gynecol Oncol 81 (2001) 447-455
27. Wright J.D., Herzog T.J., and Powell M.A. Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol 190 (2004) 1398-1400
28. van Rijswijk R.E., and Vermorken J.B. Drug therapy for gynaecological cancer in older women. Drugs Aging 17 (2000) 13-32
29. Balducci L. Evidence-based management of cancer in the elderly. Cancer Control 7 (2000) 368-376
30. McGuire W.P., Hoskins W.J., Brady M.F., Homesley H.D., Creasman W.T., Berman M.L., et al. Assessment of dose intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13 (1995) 1589-1599
31. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9 (1991) 389-393
32. Markman M., and Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 10 (1992) 513-514
33. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19 (2001) 1001-1007
34. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335 (1996) 1950-1955
35. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 (2006) 34-43
36. Davidson S.A., Rubin S.C., Markman M., Jones W.B., Hakes T.B., Reichman B., et al. Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol Oncol 41 (1991) 101-106
37. Makhija S., Leitao M., Sabbatini P., Bellin N., Almadrones L., Leon L., et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol 81 (2001) 77-81
38. Walker J.L., Armstrong D.K., Huang H.Q., Fowler J., Webster K., Burger R.A., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 100 (2006) 27-32
39. Gronlund B., Hogdall C., Hansen H.H., and Engelholm S.A. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer 94 (2002) 1961-1967
40. Rockwood K., Stadnyk K., MacKnight C., McDowell I., Hebert R., and Hogan D.B. A brief clinical instrument to classify frailty in elderly people. Lancet 353 (1999) 205-206
41. Extermann M., Overcash J., Lyman G.H., Parr J., and Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16 (1998) 1582-1587
42. Hurria A., Gupta S., Zauderer M., Zuckerman E.L., Cohen H.J., Muss H., et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104 (2005) 1998-2005